TY - JOUR
T1 - Neutron contamination in radiotherapy
T2 - Estimation of second cancers based on measurements in 1377 patients
AU - Expósito, Maite R.
AU - Sánchez-Nieto, Beatriz
AU - Terrón, José A.
AU - Domingo, Carles
AU - Gómez, Faustino
AU - Sánchez-Doblado, Francisco
N1 - Funding Information:
The authors are indebted to the Andalusian Health Service (SAS) for its support through a University Law (LOU) contract with the University of Seville, to the Spanish Ministry of Science and Technology for its support through grant agreements PET2006_0412 and FIS2009-10634 , and especially to the Spanish Nuclear Security Council for its support through a specific agreement with the University of Seville for measuring neutron doses in radiotherapy patients.
PY - 2013/5
Y1 - 2013/5
N2 - Purpose Second cancer, as a consequence of a curative intent radiotherapy (RT), represents a growing concern nowadays. The unwanted neutron exposure is an important contributor to this risk in patients irradiated with high energy photon beams. The design and development by our group of a neutron digital detector, together with the methodology to estimate, from the detector readings, the neutron equivalent dose in organs, made possible the unprecedented clinical implementation of an online and systematic neutron dosimetry system. The aim of this study was to systematically estimate neutron equivalent dose in organs of a large patient group treated in different installations. Patients and methods Neutron dosimetry was carried out in 1377 adult patients at more than 30 different institutions using the new neutron digital detector located inside the RT room. Second cancer risk estimates were performed applying ICRP risk coefficients. Results Averaged equivalent dose in organs ranges between 0.5 mSv and 129 mSv depending on the type of treatment (dose and beam-on time), the distance to isocenter and the linac model. The mean value of the second cancer risk for our patient group is 1.2%. Reference values are proposed for an overall estimation of the risks in 15 linac models (from 2.8 × 10-5 to 62.7 × 10-5 %/MU). Conclusions The therapeutic benefit of RT must outweigh the second cancer risk. Thus, these results should be taken into account when taking clinical decisions regarding treatment strategy choice during RT planning.
AB - Purpose Second cancer, as a consequence of a curative intent radiotherapy (RT), represents a growing concern nowadays. The unwanted neutron exposure is an important contributor to this risk in patients irradiated with high energy photon beams. The design and development by our group of a neutron digital detector, together with the methodology to estimate, from the detector readings, the neutron equivalent dose in organs, made possible the unprecedented clinical implementation of an online and systematic neutron dosimetry system. The aim of this study was to systematically estimate neutron equivalent dose in organs of a large patient group treated in different installations. Patients and methods Neutron dosimetry was carried out in 1377 adult patients at more than 30 different institutions using the new neutron digital detector located inside the RT room. Second cancer risk estimates were performed applying ICRP risk coefficients. Results Averaged equivalent dose in organs ranges between 0.5 mSv and 129 mSv depending on the type of treatment (dose and beam-on time), the distance to isocenter and the linac model. The mean value of the second cancer risk for our patient group is 1.2%. Reference values are proposed for an overall estimation of the risks in 15 linac models (from 2.8 × 10-5 to 62.7 × 10-5 %/MU). Conclusions The therapeutic benefit of RT must outweigh the second cancer risk. Thus, these results should be taken into account when taking clinical decisions regarding treatment strategy choice during RT planning.
KW - Neutron
KW - Peripheral dose
KW - Second cancer risk
UR - https://www.scopus.com/pages/publications/84879018535
U2 - 10.1016/j.radonc.2013.03.011
DO - 10.1016/j.radonc.2013.03.011
M3 - Article
C2 - 23601351
AN - SCOPUS:84879018535
SN - 0167-8140
VL - 107
SP - 234
EP - 241
JO - Radiotherapy and Oncology
JF - Radiotherapy and Oncology
IS - 2
ER -